Cel-Sci Corporation has filed a patent application covering the use of its immunotherapy product Multikine for the enhancement of the response to and success of radiation and chemotherapy. The supporting data was derived from a clinical trial with Multikine in head & neck cancer patients. That data has recently been accepted for publication by a leading peer-reviewed oncology journal.
Data from this trial indicated that the use of Cel-Sci's immunotherapy drug Multikine during a two-week period prior to surgical intervention affected the tumor such that the residual tumor cells became more susceptible to follow-on treatment with radiation, and possibly chemotherapy. This is a very important new finding which may lead to a better and more effective treatment for many forms of cancer.
Geert Kersten, Chief Executive Officer of Cel-Sci, said, "This patent should protect one of the largest applications for Multikine, namely its use to increase the success of radiation, and possibly chemotherapy, for a long time."
Multikine, a natural mixture of human cytokines, has to date been tested in over 190 cancer, HIV and HIV/HPV infected patients with no severe adverse events related to Multikine administration. It is under clinical investigation for the treatment of head & neck cancer and for the treatment of cervical dysplasia caused by the Human Papilloma Virus (HPV). Multikine is an immune adjuvant with direct anti-viral and anti-cancer activities, assisting in host immune response reconstitution.